Medeiros A A, Kent R L, O'Brien T F
Antimicrob Agents Chemother. 1974 Dec;6(6):791-801. doi: 10.1128/AAC.6.6.791.
A survey of clinical isolates from a hospital laboratory showed that Escherichia coli could be grouped into three classes of beta-lactam-antibiotic resistance by results of routine susceptibility testing to ampicillin, cephalothin, and carbenicillin. E. coli highly resistant to ampicillin and carbenicillin but not to cephalothin (class I) were found to have one of two levels of R factor-mediated, periplasmic-beta-lactamase which resembled R(TEM) and was located behind a permeability barrier to penicillins but not to cephalosporins. This permeability barrier appeared to act synergistically with the beta-lactamase in producing high levels of resistance to penicillins. E. coli highly resistant to ampicillin and cephalothin but not carbenicillin (class II) were found to have a beta-lactamase with predominantly cephalosporinase activity which was neither transferable nor releasable by osmotic shock. E. coli moderately resistant to one or to all three of these antibiotics (class III) were found to have low levels of different beta-lactamases including a transferable beta-lactamase which resembled R(1818). Thus, different mechanisms producing resistance to beta-lactam antibiotics could be deduced from the patterns of resistance to ampicillin, cephalothin, and carbenicillin found on routine susceptibility testing. E. coli of class I were much more prevalent than the other classes and the proportion of E. coli that were class I increased with duration of patient hospitalization. The incidence of class I E. coli rose only slightly over the past 7 years and that of class II E. coli remained constant despite increased usage of both cephalothin and ampicillin. These observations emphasize that the properties of the apparently limited number of individual resistance mechanisms that exist in a bacterial flora, such as their genetic mobility and linkages and the spectrum of their antibiotic inactivating enzymes and permeability barriers, may govern the effect that usage of an antibiotic has upon the prevalence of resistance to it and to other antibiotics.
一项对某医院实验室临床分离菌株的调查显示,通过对氨苄西林、头孢噻吩和羧苄西林进行常规药敏试验的结果,大肠杆菌可分为三类对β-内酰胺抗生素耐药的类型。发现对氨苄西林和羧苄西林高度耐药但对头孢噻吩不耐药的大肠杆菌(I类)具有两种水平之一的R因子介导的周质β-内酰胺酶,该酶类似于R(TEM),位于对青霉素但不对头孢菌素的通透性屏障之后。这种通透性屏障似乎与β-内酰胺酶协同作用,产生对青霉素的高水平耐药性。发现对氨苄西林和头孢噻吩高度耐药但对羧苄西林不耐药的大肠杆菌(II类)具有一种主要具有头孢菌素酶活性的β-内酰胺酶,该酶既不能转移也不能通过渗透压休克释放。发现对这三种抗生素中的一种或全部三种中度耐药的大肠杆菌(III类)具有低水平的不同β-内酰胺酶,包括一种类似于R(1818)的可转移β-内酰胺酶。因此,从常规药敏试验中发现的对氨苄西林、头孢噻吩和羧苄西林的耐药模式可以推断出产生对β-内酰胺抗生素耐药的不同机制。I类大肠杆菌比其他类型更为普遍,并且I类大肠杆菌的比例随着患者住院时间的延长而增加。在过去7年中,I类大肠杆菌的发生率仅略有上升,尽管头孢噻吩和氨苄西林的使用量增加,但II类大肠杆菌的发生率保持不变。这些观察结果强调,细菌菌群中存在的明显数量有限的个体耐药机制的特性,如它们的遗传流动性和连锁关系以及它们的抗生素灭活酶和通透性屏障的谱,可能决定抗生素使用对其及其他抗生素耐药性流行率的影响。